Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion

• Main Authors: A. S. Kolbin (Author), I. A. Vilum (Author), Yu. E. Balykina (Author), M. A. Proskurin (Author)
• Format: Knjiga
• Izdano: Izdatelstvo OKI, 2018-05-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

We have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of ibrutinib in the first line of therapy of chronic lymphocytic leukemia at patients with a 17p deletion. Research was conducted from a position of the state health system by means of mathematical modeling....